These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26337137)

  • 1. Tetrazolylhydrazides as Selective Fragment-Like Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A.
    Rüger N; Roatsch M; Emmrich T; Franz H; Schüle R; Jung M; Link A
    ChemMedChem; 2015 Nov; 10(11):1875-83. PubMed ID: 26337137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-Biphenylalanine- and 3-Phenyltyrosine-Derived Hydroxamic Acids as Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A.
    Morera L; Roatsch M; Fürst MC; Hoffmann I; Senger J; Hau M; Franz H; Schüle R; Heinrich MR; Jung M
    ChemMedChem; 2016 Sep; 11(18):2063-83. PubMed ID: 27505861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-Based Screening of Tetrazolylhydrazide Inhibitors versus KDM4 Histone Demethylases.
    Małecki PH; Rüger N; Roatsch M; Krylova O; Link A; Jung M; Heinemann U; Weiss MS
    ChemMedChem; 2019 Nov; 14(21):1828-1839. PubMed ID: 31475772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel inhibitors of lysine (K)-specific Demethylase 4A with anticancer activity.
    Lee HJ; Kim BK; Yoon KB; Kim YC; Han SY
    Invest New Drugs; 2017 Dec; 35(6):733-741. PubMed ID: 28905188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitor scaffold for the histone lysine demethylase KDM4C (JMJD2C).
    Leurs U; Clausen RP; Kristensen JL; Lohse B
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5811-3. PubMed ID: 22917519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: introduction of an additional carboxyl group at the C-2 position of quinoline.
    Feng T; Li D; Wang H; Zhuang J; Liu F; Bao Q; Lei Y; Chen W; Zhang X; Xu X; Sun H; You Q; Guo X
    Eur J Med Chem; 2015 Nov; 105():145-55. PubMed ID: 26491978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the histone demethylase KDM4A in cancer.
    Guerra-Calderas L; González-Barrios R; Herrera LA; Cantú de León D; Soto-Reyes E
    Cancer Genet; 2015 May; 208(5):215-24. PubMed ID: 25633974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substituted 2-(2-aminopyrimidin-4-yl)pyridine-4-carboxylates as potent inhibitors of JumonjiC domain-containing histone demethylases.
    Roatsch M; Robaa D; Pippel M; Nettleship JE; Reddivari Y; Bird LE; Hoffmann I; Franz H; Owens RJ; Schüle R; Flaig R; Sippl W; Jung M
    Future Med Chem; 2016 Sep; 8(13):1553-71. PubMed ID: 26971619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a potent and selective inhibitor of histone lysine demethylase KDM4D.
    Fang Z; Liu Y; Zhang R; Chen Q; Wang T; Yang W; Fan Y; Yu C; Xiang R; Yang S
    Eur J Med Chem; 2021 Nov; 223():113662. PubMed ID: 34237635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Clinically Used Iron Chelator Deferasirox Is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases.
    Roatsch M; Hoffmann I; Abboud MI; Hancock RL; Tarhonskaya H; Hsu KF; Wilkins SE; Yeh TL; Lippl K; Serrer K; Moneke I; Ahrens TD; Robaa D; Wenzler S; Barthes NPF; Franz H; Sippl W; Lassmann S; Diederichs S; Schleicher E; Schofield CJ; Kawamura A; Schüle R; Jung M
    ACS Chem Biol; 2019 Aug; 14(8):1737-1750. PubMed ID: 31287655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors.
    Dalvi MP; Wang L; Zhong R; Kollipara RK; Park H; Bayo J; Yenerall P; Zhou Y; Timmons BC; Rodriguez-Canales J; Behrens C; Mino B; Villalobos P; Parra ER; Suraokar M; Pataer A; Swisher SG; Kalhor N; Bhanu NV; Garcia BA; Heymach JV; Coombes K; Xie Y; Girard L; Gazdar AF; Kittler R; Wistuba II; Minna JD; Martinez ED
    Cell Rep; 2017 May; 19(8):1669-1684. PubMed ID: 28538184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Scaffolds of Cell-Active Histone Demethylase Inhibitors Identified from High-Throughput Screening.
    Wang W; Marholz LJ; Wang X
    J Biomol Screen; 2015 Jul; 20(6):821-7. PubMed ID: 25883088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural definitions of Jumonji family demethylase selectivity.
    Pilka ES; James T; Lisztwan JH
    Drug Discov Today; 2015 Jun; 20(6):743-9. PubMed ID: 25555749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a Highly Selective Cell-Active Inhibitor of the Histone Lysine Demethylases KDM2/7.
    Gerken PA; Wolstenhulme JR; Tumber A; Hatch SB; Zhang Y; Müller S; Chandler SA; Mair B; Li F; Nijman SMB; Konietzny R; Szommer T; Yapp C; Fedorov O; Benesch JLP; Vedadi M; Kessler BM; Kawamura A; Brennan PE; Smith MD
    Angew Chem Int Ed Engl; 2017 Dec; 56(49):15555-15559. PubMed ID: 28976073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors.
    Hamada S; Suzuki T; Mino K; Koseki K; Oehme F; Flamme I; Ozasa H; Itoh Y; Ogasawara D; Komaarashi H; Kato A; Tsumoto H; Nakagawa H; Hasegawa M; Sasaki R; Mizukami T; Miyata N
    J Med Chem; 2010 Aug; 53(15):5629-38. PubMed ID: 20684604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based design and discovery of potent and selective KDM5 inhibitors.
    Nie Z; Shi L; Lai C; O'Connell SM; Xu J; Stansfield RK; Hosfield DJ; Veal JM; Stafford JA
    Bioorg Med Chem Lett; 2018 May; 28(9):1490-1494. PubMed ID: 29627262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.
    Chin YW; Han SY
    Expert Opin Ther Pat; 2015 Feb; 25(2):135-44. PubMed ID: 25468267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors.
    Korczynska M; Le DD; Younger N; Gregori-Puigjané E; Tumber A; Krojer T; Velupillai S; Gileadi C; Nowak RP; Iwasa E; Pollock SB; Ortiz Torres I; Oppermann U; Shoichet BK; Fujimori DG
    J Med Chem; 2016 Feb; 59(4):1580-98. PubMed ID: 26699912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3 inhibitors.
    Hu J; Wang X; Chen L; Huang M; Tang W; Zuo J; Liu YC; Shi Z; Liu R; Shen J; Xiong B
    Bioorg Med Chem Lett; 2016 Feb; 26(3):721-725. PubMed ID: 26776360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays.
    Le Bihan YV; Lanigan RM; Atrash B; McLaughlin MG; Velupillai S; Malcolm AG; England KS; Ruda GF; Mok NY; Tumber A; Tomlin K; Saville H; Shehu E; McAndrew C; Carmichael L; Bennett JM; Jeganathan F; Eve P; Donovan A; Hayes A; Wood F; Raynaud FI; Fedorov O; Brennan PE; Burke R; van Montfort RLM; Rossanese OW; Blagg J; Bavetsias V
    Eur J Med Chem; 2019 Sep; 177():316-337. PubMed ID: 31158747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.